Comparison of Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients with Ventilator Associated-pneumonia to Pseudomonas Aeruginosa in Intensive Care Units
Latest Information Update: 01 Oct 2024
Price :
$35 *
At a glance
- Drugs Ceftolozane/tazobactam (Primary)
- Indications Pseudomonal infections; Ventilator associated pneumonia
- Focus Pharmacokinetics
- Acronyms CEFTOREA
- 25 Sep 2024 Planned End Date changed from 1 Feb 2023 to 1 Feb 2025.
- 25 Sep 2024 Planned primary completion date changed from 1 Feb 2023 to 1 Feb 2025.
- 06 Jun 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified June 2022).